However, clinical evidence remains conflicting: expression of PTP-1B has been identified as a favorable prognostic factor for survival in breast cancer (17); overexpression of PTP-1B has also been proposed as a marker for response to chemotherapy in high-grade serous carcinoma (18). The gene discussed is PTPN1; the disease is serous adenocarcinoma.